Digital Therapeutics Patents

Digital therapeutics (DTx) are evidence-based therapeutic interventions driven by high-quality software programs to prevent; manage; or treat a medical disorder — with a growing number of FDA-cleared products and associated patent portfolios: MAJOR FDA-CLEARED DIGITAL THERAPEUTICS AND THEIR IP: BEHAVIORAL HEALTH: PEAR THERAPEUTICS (BANKRUPT 2023; IP ACQUIRED): reSET (SUD — first FDA-cleared PDT 2017); reSET-O (OUD); Somryst (insomnia CBT-I); specific IP: specific prescription digital therapeutic architecture (specific clinician prescription + specific patient app activation code + specific engagement data reporting to clinician portal; specific FDA 510(k) Class II SaMD architecture); specific CBT module delivery (specific contingency management reward delivery algorithm; specific behavioral economics incentive timing for specific engagement optimization); FREESPIRA: specific PTSD + panic disorder digital therapeutic (specific capnometry biofeedback: specific CO2 sensor + specific breathing guidance algorithm for specific hyperventilation correction; specific respiratory rate + ETCO2 target biofeedback loop); REJOYN (ALTO NEUROSCIENCE; BIG HEALTH-RELATED): specific first FDA-cleared prescription app for adjunctive treatment of MDD 2023 (specific cognitive training + specific CBT module sequence + specific engagement tracking + specific prescriber reporting); CHRONIC DISEASE MANAGEMENT: PROPELLER HEALTH (RESMED ACQUISITION): specific connected inhaler sensor (specific acoustic + specific vibration sensor for specific actuation detection; specific GPS + specific time stamp for specific trigger identification; specific adherence + specific trigger environment correlation algorithm); specific COPD + specific asthma management platform; LIVONGO (TELADOC ACQUISITION): specific diabetes management platform (specific cellular blood glucose meter; specific real-time ML coaching trigger based on specific reading threshold + specific member history + specific contextual rule for specific in-the-moment coaching message); NOOM: specific behavioral weight management (specific CBT + specific positive psychology curriculum delivery algorithm; specific logging + specific ML engagement prediction for specific session timing optimization); OMADA HEALTH: specific digital chronic disease prevention (specific DPP — Diabetes Prevention Program — delivery algorithm for specific structured curriculum + specific health coach interaction model).

Digital therapeutics IP revolves around three core innovation areas — therapeutic content delivery algorithms; patient engagement optimization; and clinical outcome measurement — each with distinct patentability characteristics: THERAPEUTIC CONTENT DELIVERY ALGORITHM PATENTS: CBT MODULE DELIVERY: specific adaptive CBT session sequencing algorithm (specific symptom severity score from specific PHQ-9 or GAD-7 or validated scale → specific module selection algorithm for specific within-session technique: specific behavioral activation + specific cognitive restructuring + specific exposure hierarchy; specific specific session length adaptation based on specific engagement signal); specific exposure hierarchy algorithm (specific fear ladder construction + specific specific exposure step graduation algorithm based on specific SUDs (subjective units of distress) measurement within specific session); specific therapist-assisted vs. self-directed branching (specific engagement threshold → specific automated escalation to human coach for specific high-risk profile); BEHAVIORAL ECONOMICS IN DTx: specific loss aversion framing in specific progress visualization algorithm; specific commitment device algorithm (specific patient goal setting + specific penalty commitment for specific adherence motivation); specific variable reward schedule algorithm (specific intermittent reinforcement timing for specific healthy behavior logging retention); ENGAGEMENT OPTIMIZATION PATENT LANDSCAPE: SPECIFIC PATENTABLE ENGAGEMENT INNOVATIONS: specific optimal notification timing algorithm (specific ML model from specific individual engagement history: specific session open times + specific days + specific contextual features → specific push notification timing for specific session initiation probability maximization); specific session length optimization (specific time-in-app engagement pattern + specific therapeutic completion ratio + specific dropout prediction → specific module length adaptation for specific individual adherence); specific gamification algorithm (specific specific achievement badge + specific streak system for specific daily engagement maintenance with specific habituation prevention through specific novel badge category introduction); specific social comparison algorithm (specific anonymized peer comparison + specific normative feedback for specific healthy behavior motivation); CLINICAL OUTCOME MEASUREMENT: specific PRO (Patient Reported Outcome) algorithm (specific EMA (Ecological Momentary Assessment) signal integration: specific multiple daily PHQ-2 + specific specific validation against specific baseline PHQ-9 + specific specific alarm threshold for specific crisis detection); specific digital biomarker (specific smartphone passive sensing: specific accelerometer + specific screen time + specific GPS + specific social interaction → specific depression episode detection with specific PHQ-9 correlation coefficient).

Chronic disease digital therapeutics — particularly for diabetes; cardiovascular risk; and respiratory disease — represent the largest commercial opportunity in digital health, with a growing patent landscape: DIABETES DIGITAL THERAPEUTICS PATENT LANDSCAPE: LIVONGO (TELADOC): specific cellular CGM-connected coaching (specific CGM reading → specific ML model → specific real-time coaching message calibrated to specific reading context + member history); DARIO HEALTH: specific all-in-one smartphone glucometer (specific universal audio jack glucometer dongle — NOTE: similar to Square hardware patent US8,584,947 audio jack design precedent); specific mobile diabetes management platform; INSULET OMNIPOD: specific tubeless patch pump (specific specific adhesive patch + specific cannula insertion mechanism + specific transcutaneous insulin delivery without tubing); ONE DROP: specific AI-driven diabetes coaching; PROPELLER HEALTH / RESMED: specific connected inhaler for COPD + asthma (specific MEMS acoustic sensor for specific actuation detection with specific vibration pattern differentiation vs. ambient noise); specific GPS + time-of-day trigger pattern identification algorithm for specific personalized asthma management; specific adherence correlation with specific outcome prediction; CARDIOVASCULAR DIGITAL THERAPEUTICS: HEARTFLOW: specific coronary CT + computational fluid dynamics FFRct (specific specific meshing algorithm + specific steady-state Navier-Stokes solver for specific fractional flow reserve calculation from CT scan without catheterization); specific FDA-cleared SaMD for specific CAD assessment; ALIVECOR KARDIA: specific ECG mobile device (specific fingertip ECG electrode on phone case; specific single-lead ECG ML algorithm for specific AFib detection with specific sensitivity/specificity vs. 12-lead reference); APPLE WATCH ECG: specific single-lead ECG from specific wrist electrode + specific AFib detection algorithm with specific FDA clearance; IRHYTHM ZIOPATCH: specific extended-wear single-lead ECG patch (specific adhesive electrode + specific specific data storage + specific arrhythmia algorithm for specific 14-day continuous monitoring); ONCOLOGY DIGITAL THERAPEUTICS: VOLUNTIS (SANOFI ACQUISITION): specific cancer treatment decision support algorithm (specific symptom + specific side effect input + specific specific guideline-consistent dose modification recommendation for specific specific tumor board protocol); specific patient engagement in oncology adherence; NAVIGATING DTx IP DIFFERENTIATION: specific combination of specific validated algorithm + specific patient-specific dosing + specific outcome-linked feedback loop = strongest claim structure for chronic disease DTx.

Digital therapeutics startups must navigate the intersection of pharmaceutical-equivalent clinical validation; medical device regulation; and software IP strategy — requiring a multi-layered approach: DIGITAL THERAPEUTICS STARTUP IP STRATEGY: UNDERSTAND THE DTx IP LANDSCAPE: DTx AS SOFTWARE PATENTS: DTx patents are primarily method claims (software process claims) + system claims (computing system + specific hardware integration) — same § 101 challenges as software patents generally but strengthened by clinical validation data; FDA CLEARANCE AS MOAT: 510(k) clearance or De Novo authorization creates significant barrier to competitive entry; clinical validation data required for FDA is also the specific performance measurement needed for strong patent claims; DTx ALLIANCE STANDARDS: DTx Alliance classification framework (Classes I-III) informs claim scope for specific therapeutic application class; LAYERED IP STRATEGY: LAYER 1 — THERAPEUTIC ALGORITHM: specific CBT/DBT/ACT module delivery algorithm + specific engagement optimization + specific clinical outcome measurement; LAYER 2 — HARDWARE INTEGRATION: specific sensor integration (specific connected device: glucometer; spirometer; ECG; CGM; inhaler sensor + specific data integration algorithm for specific therapeutic feedback loop); LAYER 3 — CLINICAL VALIDATION DATA: specific AUC + sensitivity/specificity on specific labeled clinical dataset from specific controlled trial anchors patent claims; LAYER 4 — REAL-WORLD EVIDENCE: post-market RWE from specific patient population + specific health outcome improvement = continuation patent strategy; PROVISIONAL PATENT TIMING: file provisional BEFORE: (1) FDA Pre-Submission meeting (any innovations disclosed in Pre-Sub become potentially public); (2) ISPOR/ADA/AHA presentation of clinical data; (3) any abstract or poster submitted to conference; § 101 STRATEGY: WHAT FAILS: method of treating disease using software = natural phenomenon; cognitive behavioral therapy = mental steps; psychological method = abstract; WHAT SURVIVES: specific computing architecture + specific sensor hardware + specific therapeutic algorithm + specific clinical outcome (specific AUC/sensitivity/specificity) on specific disease indication; KEY FTO CONSIDERATIONS: PEAR THERAPEUTICS: reSET/reSET-O prescription PDT architecture + contingency management algorithm (acquired from bankruptcy — investigate current ownership); FREESPIRA: capnometry biofeedback CO2 sensor algorithm; PROPELLER: connected inhaler MEMS sensor + GPS trigger pattern; LIVONGO: CGM-connected ML coaching trigger; HEARTFLOW: FFRct Navier-Stokes CFD algorithm; ALIVECOR: fingertip ECG + ML AFib detection; APPLE: wrist ECG AFib; iRhythm: 14-day patch ECG arrhythmia detection.